Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997

Clinical Infectious Diseases

Volumn 29, Issue 3, 1999, Pages 595-607

  Diekema, Daniel J ^a   Pfaller, M A ^b   Jones, R N ^b   Doern, G V ^b   Winokur, P L ^b   Gales, A C ^b   Sader, H S ^b   Kugler, K ^b   Beach, M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SPARFLOXACIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; KLEBSIELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0032860520     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598640     Document Type: Article

References (28)

1. Martin MA. Epidemiology and clinical impact of gram-negative sepsis. Infect Dis Clin North Am 1991;5:739-52.
2. Bune RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-69.
3. Parrillo J. Pathogenctic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
4. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;21:584-602.
5. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Intern Med 1962;110:856-64.
6. Bryant RT, Hood AF, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971,127:120-8.
7. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983;5:629-38.
8. Jones RN. Important and emerging beta-lactamase mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998;31:461-6.
9. Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended spectrum beta-lactaniases. Eur J Clin Microbiol Infect Dis 1994;13(suppl 1):17-29.
10. Sanders WB, Sanders CS. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988;10:830-8.
11. Turnidge J. Epidemiology of quinolone resistance: Eastern hemisphere. Drugs 1995;49(suppl 2):43-7.
12. Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995;49(suppl 2):36-42.
13. Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-beta-lactamasc-producing Pseudomanas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenerns. Antimicrob Agents Chemother 1996;40:349-53.
14. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology, 1995.
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grow aerobically: approved standard. NCCLS document M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: supplemental tables, NC-CLS document M100-S8. Wayne, PA; National Committee for Clinical Laboratory Standards, 1998.
17. Pfaller MA, Wendt C, Hollis RJ, et al. Comparative evaluation of an automated ribotyping system versus PFGE for epidemiologic typing of clinical isolates of E. coli and P. aeruginosa from the patients with recurrent gram-negative bacteremia. Diagn Microbiol Infect Dis 1996; 25:1-8.
18. Pfaller MA, Jones RN, Doern GV, et al. Survey of bloodstream infections due to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America for the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 1999;33:283-97.
19. Banerjce SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91(suppl 3B):86S-9S.
20. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enteroeoccal bloodstream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95-102.
21. Pfaller MA, Jones RN, Doem GV, et al. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762-70.
22. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic resistant Klebsiella and Excherichia coli in nursing homes. JAMA 1999;281:517-23.
23. Venezuelan Antimicrobial Resistance Study Group, Pfaller MA, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. Diagn Microbiol Infect Dis 1998;30:45-52.
24. Colombian Antimicrobial Resistance Study Group, Jones RN, Salazar JC, Pfaller MA, Doern GV. Multicenter evaluation of antimicrobial resistance to six broad spectrum β-lactams in Colombia using the Etest method. Diagn Microbiol Infect Dis 1997;29:265-72.
25. Jones RN, Pfaller MA, Doern GV, Erwin ME, Hollis RJ, Cefepime Study Group. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis 1998; 30:215-28.
26. Sanders WE, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996;23:454-61.
27. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
28. Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ 1998;317:647-50.